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Secretary-General of the United Nations, who will in turn 
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Drugs (CND). 
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meeting, which was dedicated to the review of cannabis 
and its component substances. This included a critical 
review of cannabidiol and pre-reviews of cannabis 
plant and resin; extracts and tinctures of cannabis; Δ9-
tetrahydrocannabinol ((Δ9-THC) ); and isomers of THC. 
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International Drug Control Conventions. The Committee 
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a critical review of cannabis plant and resin; extracts and 
tinctures of cannabis; Δ9-THC and isomers of Δ9-THC.
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1. Introduction
The fortieth meeting of the World Health Organization (WHO) Expert 
Committee on Drug Dependence (ECDD) was held from 4–7 June 2018 at WHO 
headquarters in Geneva, Switzerland. The meeting was dedicated to the review of 
cannabis and its component substances.
Commission on Narcotic Drugs (CND) Resolution 52/5 noted that the 
health effects of cannabis had not been recently reviewed and requested that 
the WHO ECDD provide an updated report. The thirty-seventh ECDD (2015) 
requested that the ECDD Secretariat begin collecting data that would inform the 
review of cannabis, cannabis resin and extracts and tinctures of cannabis at a 
future meeting. Two reports on cannabis were presented in 2016 at the thirty-
eighth meeting of the ECDD.
The thirty-eighth ECDD recognized:
1. the increase in the use of cannabis and its components for medical 
purposes;
2. the emergence of new cannabis-related pharmaceutical preparations 
for therapeutic use; and
3. that cannabis had never been subject to a formal pre-review or criti-
cal review by the ECDD.
Therefore, the Committee recommended that pre-reviews of cannabis 
and its component substances be evaluated at an ECDD meeting specifically 
dedicated to those substances.
In response to those recommendations, the fortieth meeting of the 
ECDD was designated a special session dedicated to the review of cannabis and 
cannabis-related components that are currently scheduled under the 1961 and 
1971 Conventions. A separate pre-review of cannabidiol was carried out during 
the thirty-ninth meeting of the ECDD.
Dr Mariângela Simão, Assistant Director-General for Access to Medicines, 
Vaccines and Health Products opened the meeting by welcoming all participants 
on behalf of the WHO Director-General. She then thanked the ECDD members 
for the time and effort they had dedicated to the review of the substances on 
the agenda of the meeting. Dr Simão reiterated the mandate of WHO under 
the 1961 Single Convention on Narcotic Drugs (1) and the 1971 Convention 
on Psychotropic Substances (2) to undertake the assessment of psychoactive 
substances with potential for abuse and dependence and that cause harm to 
health. She explained that, where relevant, the importance of therapeutic use of 
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these substances is also assessed. She emphasized that evidence-based assessment 
of psychoactive substances as mandated by the International Drug Control 
Conventions is central to the work of the ECDD. Participants were reminded 
that they were acting in their personal capacities and not as representatives of 
their governments.
Mr Jakob Quirin of the WHO Office of the Legal Counsel then reminded 
the participants that the Expert Committee is convened in accordance with 
WHO’s Regulations for expert advisory panels (3) and the Guidance on the WHO 
review of psychoactive substances for international control (4). In accordance with 
this guidance, the functions of the ECDD are to review information available to 
it on substances being considered for international control and for exemptions, 
and to advise the Director-General on such control.
The members of the Expert Committee elected a chair, co-chair and a 
rapporteur. The chair welcomed all participants and the agenda, as proposed by 
the Secretariat, was approved.
3Declarations of interest
The competing interests that may occur in health care result in the potential for 
conflicts of interest and may lead to biased generation or assessment of evidence 
and to misinformed health care policies. WHO has stringent policies for avoiding, 
or at least limiting, conflicts of interest, particularly in the development of official 
guidance documents that affect health care. As declaration of conflict of interests 
is insufficient to neutralize potentially harmful effects, the Organization has 
accurate mechanisms for identifying relevant conflicts of interest and approaches 
for managing such conflicts (for example, exclusion of members, recusal from 
participation in meeting sessions, restricting participation), thus ensuring the 
validity and transparency of the decision-making process and the credibility of 
the Expert Committee’s decisions. 
Before the opening of the meeting and in accordance with WHO policy, 
all members of the Expert Committee and all temporary advisers attending 
the meeting submitted written disclosures of potential conflicts of interest 
that may affect, or may be reasonably perceived to affect, their objectivity and 
independence in relation to the subject matter of the meeting. The WHO ECDD 
Secretariat received the following disclosures and sought the advice of the Office 
of Compliance, Risk Management and Ethics:
Professor Bruna Brands, Expert Panel Member, declared having received 
research support from the Canadian Institutes of Health Research and Public 
Safety Canada. The funding was to investigate the effects of cannabis on driving 
performance. 
Professor Raka Jain, Expert Panel Member, declared several interests not 
pertaining to the substances being reviewed at the fortieth meeting of the ECDD. 
This included research funding from the Indian government. 
Professor Jason White, Expert Panel Member, declared that he acts as an 
expert witness for the courts on judicial matters relating to cannabis. 
Dr Giuseppe Cannazza, Temporary Adviser, declared receiving research 
support from Linnea pharmaceuticals to investigate the chemical composition of 
extracts of industrial hemp.
Dr Jenny Wiley, Temporary Adviser, declared that she receives research 
support from the United States National Institute of Drug Abuse (NIDA), 
National Institutes of Health and the Food and Drug Administration (FDA) to 
carry out research on cannabinoids.
Declarations of interest
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Dr Kevin Hill, Temporary Adviser, declared that he receives research 
support from US NIDA for the treatment of cannabis-related disorders.
Dr Jonathon Arnold, Temporary Adviser, declared that he holds 
provisional patents on minor cannabinoids. He has provided reports on medical 
cannabis to the state government in Australia. These contracts ceased in 2016. 
His employer, University of Sydney, contributed to his travel costs to attend the 
ECDD meeting.
The disclosed interests were considered by the Secretariat of the fortieth 
ECDD as not in conflict with any issues to be discussed at the meeting or with 
the recommendations to be issued by the Expert Committee. No other interests 
declared by members of the Expert Committee or temporary advisers were 
deemed relevant to the work of the group.
2. WHO Expert Committee on Drug Dependence (ECDD): review procedures and processes 
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2. WHO Expert Committee on Drug Dependence (ECDD): 
review procedures and processes 
2.1 Pre-reviews and critical reviews
As per WHO procurement guidelines, WHO issued a public Request for 
Proposals for authors of pre-review reports that would inform the deliberations of 
the fortieth ECDD. Proposals were solicited from individuals with demonstrated 
scientific expertise relating to cannabis and cannabis-related substances in the 
fields of chemistry, toxicology, pharmacology, epidemiology and therapeutic use. 
2.2 Member State questionnaires 
At its 126th session in January 2010, the Executive Board approved the publication 
Guidance on the WHO review of psychoactive substances for international control 
(4) (Annex 6), which requires the Secretariat to request relevant information from 
ministries of health in Member States and to prepare a report for submission to 
the ECDD. 
For this purpose, a questionnaire was designed to gather information on 
the legitimate use, harmful use, status of national control and potential impact 
of international control for each substance under evaluation. As in the past, 
Member States were invited to collaborate in this process by providing accurate 
information, as requested in the questionnaires, concerning substances under 
review. 
The questionnaire was available in three languages (English, Spanish and 
French) and was open for responses between March and May 2018. Member 
States were also invited to provide additional relevant information to supplement 
their responses.
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3. Open session 
The purpose of the open session was to afford the Expert Committee the 
opportunity, before its meeting, to receive presentations and to question 
representatives of interested parties concerning data that had been provided 
about substances under review. 
The Expert Committee received presentations and written submissions 
from individuals and representatives of public institutions, private institutions 
and civil society organizations. The open session was opened by Dr Mariângela 
Simão, Assistant Director-General and chaired by Dr Gilles Forte, Coordinator. 
The session was attended by Committee members, the ECDD Secretariat and 
external observers. 
Presentations and/or statements relevant to the agenda of the fortieth 
meeting of the ECDD were made by the following participants:
 ■ Agence Nationale de Sécurité du Médicament et des Produits de 
Santé, France
 ■ Americans for Safe Access, United States of America
 ■ Amy King, United States of America
 ■ Associazione Luca Coscioni, Forum Droghe, Società della Ragione 
and DRCNet Foundation, Italy
 ■ Beckley Foundation, England
 ■ Brazilian Federal Senate Commission on Human Rights and Partici-
patory Legislation, Brazil
 ■ Caryle Hearte, United States of America
 ■ Crohn Consult, the Netherlands
 ■ Drug and Chemical Advisory Group, United States of America
 ■ Drug Policy Alliance, United States of America
 ■ Entourage Clinical Services, United States of America
 ■ Epistemonikos Foundation, Chile 
 ■ European Industrial Hemp Association, Germany
 ■ Familias con Retos Especialies, Mexico
 ■ Fields of Green for All, South Africa
 ■ For Alternative Approaches to Addiction – Think & do tank, France
 ■ Instituto RIA, Mexico
 ■ International Association for Cannabinoid Medicines, Germany
 ■ International Drug Policy Consortium, England
3. Open session
7
 ■ Julie Fry, United States of America
 ■ Mamá Cultiva, Argentina
 ■ Medical Cannabis Awareness, New Zealand
 ■ Mexico United Against Crime, Mexico
 ■ Nephrology and Urology Institute, Uruguay
 ■ PhytoSciences, United States of America
 ■ Rossner & Sohn GmBH, Germany
 ■ Scottish Youth Parliament, Scotland
 ■ Sylvie Massart, France
 ■ The Hemp Foundation, New Zealand
 ■ Tilray Global, United States of America
 ■ Veterans for Medical Cannabis Access, United States of America
 ■ Willem Scholten Consultancy, the Netherlands
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4. Briefings from international organizations on their 
work on the public health dimension of the world drug 
problem
4.1 Update from the international Narcotics Control Board
Mr Rossen Popov presented an update on behalf of the International Narcotics 
Control Board (INCB). The INCB is an independent and quasi-judicial control 
organ, established by treaty, for monitoring the implementation of the United 
Nations International Drug Control Conventions. The Board consists of 13 
members who are elected by the Economic and Social Council and who serve in 
their personal capacity, not as government representatives. Three members with 
medical, pharmacological or pharmaceutical experience are elected from a list of 
persons nominated by WHO and 10 members are elected from a list of persons 
nominated by governments. The Board also supports governments in ensuring 
the availability of narcotic drugs and psychotropic substances for medical and 
scientific purposes while preventing their diversion and abuse.
Pursuant to the Conventions, the use of narcotic drugs and psychotropic 
substances is limited to medical and scientific purposes. All other uses are 
incompatible with the international legal framework on drug control.
The Board had carefully examined the terminology related to the 
therapeutic use of cannabis. Drawing on the Single Convention on Narcotic 
Drugs of 1961, the Board had pointed out that when considering the possibility 
of using cannabis derivatives for the treatment of certain health conditions, it is 
most appropriate to avoid the notion of “medical cannabis”. This is intended to 
ensure that when reference is made to medicinal products, it is understood to 
refer to products that have been appropriately tested, have passed a full scientific 
evaluation including clinical trials and are licensed as medicines. 
A growing number of governments around the world are authorizing the 
use of cannabis derivatives for medicinal purposes. The 1961 Convention assigns 
national authorities the responsibility for permitting the use of those substances 
for medical purposes, as the Board stated in its annual report for 2003. Such 
use is permissible under the 1961 Convention as amended by the 1972 Protocol, 
provided that a number of conditions are met. This refers to the requirements of 
Articles 23 and 28 of the 1961 Convention, particularly regarding preparation 
and submission of estimates, reporting the area and geographical location of 
cultivation, the establishment of a cannabis agency, and of a licensing and import/
export authorization system. In its annual report for 2014, the Board devoted a 
special topic to the control measures applicable to programmes for the use of 
cannabinoids for medical purposes pursuant to the 1961 Convention. 
4. Briefings from international organizations on their work on the public health 
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The Board stressed in its annual report for 2017 that governments that 
are considering the medical use of cannabinoids should examine the results of 
scientific studies and medical trials. They should ensure that the prescription of 
such substances for medical use is performed with competent medical knowledge 
and supervision and that prescription practice is based on available scientific 
evidence and takes into consideration the potential side-effects.
Finally, governments should ensure that cannabinoids are made available 
to patients in line with relevant WHO guidelines and with the International Drug 
Control Conventions. 
4.2 Update from the United Nations Office on Drugs and Crime
Mr Justice Tettey presented an update on the priorities of the United Nations 
Office on Drugs and Crime (UNODC). He explained that in the outcome 
document of the special session of the United Nations General Assembly on the 
world drug problem held in April 2016, Member States reaffirmed the role of 
UNODC as the leading United Nations entity for addressing and countering the 
world drug problem. 
UNODC’s three-pronged approach to implementing this mandate 
involves: research that ensures that policy is evidence-based; a strong legal 
framework that helps states address the issues of drugs, crime and terrorism 
according to the rule of law; and an operational response that is made possible by 
the political ownership of the states concerned. UNODC delivers results through 
its headquarters in Vienna and a global network of field offices, which operate in 
more than 150 countries.
At the 2016 United Nations General Assembly Special Session on 
Drugs (UNGASS), Member States committed to implementing more than 
100 recommendations on prevention and treatment; availability of controlled 
substances for medical and scientific purposes; countering drug-related crime; 
addressing issues of human rights, gender and youth; emerging challenges; 
international cooperation and alternative development. 
To effectively address and counter the world drug problem in all its 
complexity, UNODC works with a wide range of United Nations partners, 
including WHO, INCB and other international organizations, academia and civil 
society. 
In the context of the work of the WHO ECDD, the 2016 UNGASS urged 
the sharing of information and strengthening of the capacities of the relevant 
international and regional organizations to prioritize the review of the most 
prevalent, persistent and harmful new psychoactive substances (NPS) and to 
facilitate informed scheduling decisions by the CND.
10
W
H
O
 T
ec
hn
ic
al
 R
ep
or
t S
er
ie
s N
o.
 1
01
3,
 2
01
8
WHO Expert Committee on Drug Dependence   Fortieth report
UNODC outlined the progress made to date on this priority. In 2017, 
UNODC completed the extension of its Early Warning System on New 
Psychoactive Substances to collect toxicology information on NPS. With over 
16 000 data-points on more than 810 substances identified in over 100 countries 
since monitoring started in 2013, the evidence-based identification of the most 
harmful, prevalent and persistent substances is well within the reach of the 
international community.
The trends of emergence of NPS currently show an apparent decrease in 
innovation since the peak in 2013. The recommendations of WHO have resulted 
in decisions by the CND to place more than 30 NPS under control since 2015. 
Mr Tettey described newly emerging realities on the drug markets that 
would define the priorities of UNODC for the coming years. These include the 
increasing emergence of fentanyl analogues, some of which have been implicated 
in opioid overdose deaths in North America; the tramadol crisis in West Africa, 
covered extensively in the 2018 World drug report (5); and the concomitant use 
of benzodiazepines with opioids. 
UNODC is developing an Opioid Strategy that seeks to engage international 
partners such as WHO and INCB, as well as regional partners, to help protect the 
health and welfare of humankind while ensuring access to this important class of 
medicines.
Mr Tettey concluded by expressing UNODC’s confidence that the WHO 
ECDD review of cannabis and related substances would lead to outcomes that 
continue to reflect scientific rigour and that would result in recommendations 
based on the best available evidence.
4.3 Update from the World Health Organization
Dr Gilles Forte provided an update on behalf of WHO. He explained that WHO 
has six main functions in addressing the world drug problem: 
 ■ to provide technical support to countries that do not have sufficient 
capacity of their own; 
 ■ to develop norms and standards on health issues; 
 ■ to monitor and assess global health trends in coordination with other 
agencies; 
 ■ to strengthen health systems; 
 ■ to manage research agendas; and 
 ■ to promote health security by addressing common threats and 
vulnerability. 
4. Briefings from international organizations on their work on the public health 
dimension of the world drug problem
11
Several World Health Assembly resolutions and decisions have been made 
to address the public health aspects of the world drug problem. Most recently, 
in 2017, the World Health Assembly requested the WHO Director-General to 
continue efforts to improve coordination between WHO, UNODC and INCB, 
within their existing mandates, in addressing and countering the world drug 
problem. This decision also requested the WHO Director-General to keep the 
CND appropriately informed of relevant programmes and progress. 
Dr Forte went on to describe the work of the WHO ECDD in the context 
of these decisions and resolutions. The Committee makes its recommendations 
based on a thorough evidence-based analysis of the abuse and dependence 
potential, harm to health and therapeutic uses of substances that are reviewed. 
Meetings are held annually, but, exceptionally, the Committee was to meet twice 
in 2018. 
The WHO ECDD carries out its prioritization process by determining 
the most prevalent and harmful psychoactive substances with the support of 
UNODC, INCB, regional institutions and Member States. The ECDD reviews 
both published and unpublished data from sources including the UNODC Early 
Warning System (EWA), the European Monitoring Centre for Drugs and Drug 
Addiction, Member States and the Uppsala Monitoring Centre. By collecting 
information from these sources, the ECDD ensures that enough robust data are 
available to enable a review. 
Dr Forte highlighted several priority areas for the ECDD. First, WHO 
seeks to increase its capacity to review psychoactive substances by holding annual 
meetings of the ECDD. The Committee is also seeking to expand its consideration 
of data beyond peer-reviewed publications by working more closely with 
countries and regional organizations to collect unpublished information from 
reliable sources. For substances that may present substantial or serious risk to 
public health, but for which limited data are available to meet the requirements for 
scheduling, WHO is developing a system of surveillance. The surveillance system 
is complementary to the scheduling process and aims to rapidly communicate 
the dangers of harmful substances to countries, particularly the dangers of NPS. 
WHO works to ensure access to controlled medicines within the 
International Drug Control Conventions. It also regularly updates the WHO 
Model List of Essential Medicines (EML), and reviews controlled medicines to be 
added to the EML. In addition to its work to develop and promote new guidelines 
on the management of pain, WHO supports countries in assessing the availability 
of controlled medicines, in developing balanced policies and regulations, and 
improving quantification, prescribing and use. 
12
W
H
O
 T
ec
hn
ic
al
 R
ep
or
t S
er
ie
s N
o.
 1
01
3,
 2
01
8
WHO Expert Committee on Drug Dependence   Fortieth report
5. Review of substances
At its 126th session in January 2010, the WHO Executive Board approved 
the publication Guidance on the WHO review of psychoactive substances for 
international control (4). In accordance with this document, WHO carries out its 
reviews of psychoactive substances in two steps. 
The first step is referred to as pre-review; this is a preliminary review carried 
out by the Committee to determine whether a fully documented review (critical 
review) of the substance is required. A pre-review is initiated when a proposal 
has been submitted to the Expert Committee with supporting information by (1) 
the Secretariat, (2) any member of the Expert Committee, or (3) representatives 
of other organizations invited to participate in the Expert Committee meeting. 
If a preceding meeting of the Committee found that a critical review of 
a substance is warranted, the Secretariat will prepare such a review for the next 
meeting of the Committee. However, a pre-review is not always needed and in 
certain cases a critical review can be undertaken directly.
According to the Guidance on the WHO review of psychoactive substances 
for international control (4) a critical review is initiated by the Expert Committee 
in any of the following cases:
1. there has been notification from a Party to the 1961 Single Conven-
tion on Narcotic Drugs and the 1971 Convention on Psychotropic 
Substances concerning the scheduling of a substance;
2. there has been an explicit request from CND to review a substance;
3. a pre-review of a substance has resulted in an Expert Committee rec-
ommendation for critical review; or
4. information has been brought to WHO’s attention that a substance is 
clandestinely manufactured, of especially serious risk to public health 
and society, and of no recognized therapeutic use by any Party. 
In respect of case (4), if therapeutic use of the substance is confirmed 
subsequently by any Party, the substance shall be subjected to a pre-review.
6. Cannabidiol
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6.1 Substance identification
Chemically, cannabidiol (CBD) is 2-[(6R)-3-methyl-6-prop-1-en-2-ylcyclohex-
2-en-1-yl]-5-pentylbenzene-1,3-diol. CBD is one of the naturally occurring 
cannabinoids found in cannabis plants. It is a 21-carbon terpenophenolic 
compound that is formed following decarboxylation from a cannabidiolic acid 
(CBDA) precursor, although it can also be produced synthetically. CBD has 
two stereoisomers but is normally taken to refer to the naturally occurring 
(−)-enantiomer. (+)-CBD has been synthesized but has received little attention.
6.2 Chemistry
In plants, Δ9-tetrahydrocannabinol (Δ9-THC) and CBD are derived from 
their acidic precursors Δ9- tetrahydrocannabinolic acid (THCA) and CBDA, 
respectively. Subsequent decarboxylation of THCA and CBDA via light exposure, 
heating or ageing, results in Δ9-THC or CBD. Synthetic routes are available to 
produce CBD, but some of the published methods yield only small amounts. 
There are several published methods for the analytical detection of CBD in 
various biological samples. 
6.3 Ease of convertibility into controlled substances
There is some evidence that CBD can be converted in the laboratory to 
Δ9-THC, which is controlled under the 1971 United Nations Convention on 
Psychotropic Substances. The laboratory conversion of CBD to Δ9-THC results 
in a preparation of uncertain purity. There is limited in vitro evidence that this 
conversion can occur spontaneously in the presence of acid. Overall, however, 
there is no evidence that this transformation occurs in humans after oral CBD 
administration 
6.4 General pharmacology
In clinical trials and research studies, CBD is generally administered orally as 
either a capsule or dissolved in an oil solution (for example, olive or sesame 
oil). Probably due to its poor solubility in water, the absorption of CBD from 
the gastrointestinal tract is erratic, and the resulting pharmacokinetic profile is 
variable. CBD is extensively metabolized in the liver and, as a result, bioavailability 
from oral delivery is estimated to be only 6%. CBD may preferentially accumulate 
in adipose tissues due to its high lipophilicity. In in vitro models, CBD has 
been shown to modify concentrations of other drugs through the inhibition of 
cytochrome P450 (CYP) isozymes, but it is not clear whether the same effects 
occur with clinical doses.
14
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There are two types of cannabinoid (CB) receptors: CB1, which are primarily 
located in the central nervous system with some expression in peripheral tissues, 
and CB2, which can be found in the periphery on cells with immune function, in 
the gastrointestinal tract, and at low densities in the central nervous system. CBD 
does not appear to act directly at CB1 receptors, and most studies find no agonist 
effects at this receptor. CBD also shows low affinity at CB2 receptors. 
In human and animal studies, CBD has been shown to have very different 
effects from those of Δ9-THC. In mice, CBD fails to produce the behavioural 
characteristics (for example, suppression of locomotor activity, hypothermia, 
antinociception) associated with CB1 activation, whereas Δ9-THC generates all 
the effects that occur when CB1 is activated. Neuroimaging studies in humans and 
animals have shown that CBD has effects that are generally opposite to those of 
Δ9-THC. In contrast to Δ9-THC, CBD does not affect heart rate or blood pressure 
under normal conditions. CBD may interact with the endocannabinoid system 
through indirect mechanisms and several non-endocannabinoid signalling 
systems as well, but it is not clear which, if any, of these other mechanisms are 
responsible for any of CBD’s potential clinical or other effects. 
6.5 Toxicology
In general, CBD has been found to have low toxicity, although studies are limited 
and not all potential effects have been explored. 
6.6 Adverse reactions in humans
CBD does not produce the effects that are typically seen with Δ9-THC. CBD 
has been found to be generally well tolerated with a good safety profile across 
several controlled and open-label trials investigating its potential therapeutic 
effects. Adverse events reported in clinical studies investigating the therapeutic 
possibilities of CBD have included, but have not been limited to, somnolence, 
decreased appetite, diarrhoea and fatigue.
6.7 Dependence potential
It was not possible to identify any reports on controlled studies of the physical 
dependence potential of CBD in laboratory animals or humans. Tolerance to 
CBD has not been observed.
6.8 Abuse potential
Several laboratory animal studies indicate that CBD does not produce effects 
common to many drugs of abuse, nor, more specifically, effects comparable to 
those of Δ9-THC. In particular, unlike other drugs of abuse, it does not activate 
the mesolimbic dopamine (reward) pathway in the brain or potentiate the effect 
6. Cannabidiol
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of rewarding electrical stimulation. CBD fails to show an effect in the conditioned 
place preference model of reinforcement, and its effects do not resemble those of 
Δ9-THC in the drug discrimination model of subjective drug effects.
Clinical studies have shown that even high doses of oral CBD do not cause 
Δ9-THC-like effects (for example, impairment of cognitive and psychomotor 
function, increased heart rate/tachycardia and dry mouth). When evaluated in 
healthy volunteers, administration of single oral doses of up to 600 mg of CBD 
had placebo-like effects on physiological measures and on the scales of the 
Addiction Research Centre Inventory. In a randomized, double-blind, within-
subject laboratory study in recreational cannabis users, CBD produced no 
significant psychoactive, cardiovascular or other effects at doses up to 800 mg 
orally. Overall, there is no evidence that oral CBD administration in humans 
results in clinically relevant Δ9-THC-like subjective or physiological effects. Co-
administration of oral CBD does not affect the intensity of Δ9-THC subjective 
effects. There are no case reports of abuse or dependence relating to the use of 
CBD.
6.9 Therapeutic applications, extent of therapeutic use and 
epidemiology of medical use
CBD is presently marketed in several countries in combination with Δ9-THC 
in a 1:1 ratio (Sativex®). CBD is in development for a variety of therapeutic 
applications including schizophrenia, fragile X syndrome, encephalopathies, 
childhood absence seizures, neonatal hypoxic–ischaemic encephalopathy and 
perinatal asphyxia. The clinical use of CBD is most advanced in the treatment of 
epilepsy. In clinical trials, CBD has demonstrated effectiveness for treating at least 
some forms of epilepsy, with one pure CBD product (Epidiolex®) found effective 
in clinical studies of Lennox-Gastaut syndrome (a severe form of epileptic 
encephalopathy that produces various types of seizures) and Dravet syndrome (a 
complex childhood epilepsy disorder that has a high mortality rate), which are 
often resistant to other forms of medication. 
In 2015, the US FDA granted fast-track designation for intravenous CBD 
to treat neonatal hypoxic–ischaemic encephalopathy. The European Commission 
also granted orphan designation for CBD to be used in the treatment of perinatal 
asphyxia. Currently there are no other treatments available for these conditions, 
but there is evidence of the effectiveness of CBD in animal models.
6.10 Listing in the WHO Model List of Essential Medicines
Cannabidiol is not listed in the WHO EML (20th list) or the WHO Model List of 
Essential Medicines for Children (6th list).
16
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6.11 Marketing authorizations (as a medicinal product)
One pure CBD product (Epidiolex®) was under consideration for 
registration at the time of the ECDD meeting. There are several other CBD 
products in development. 
6.12 Industrial use
Pure CBD has no legitimate industrial uses.
6.13  Non-medical use, abuse and dependence
There are no case reports of abuse or dependence relating to the non-medical use 
of pure CBD. CBD-based products are, however, used for a variety of medical 
indications in preparations that are not regulated by pharmaceutical authorities.
6.14  Nature and magnitude of public health problems related to 
misuse, abuse and dependence
No public health problems (for example, driving under the influence of drugs, 
harm to health or comorbidities) have been associated with the use of pure CBD.
6.15  Licit production, consumption and international trade
Licit production for medical research is described in section 6.11 (Marketing 
authorizations). 
6.16  Illicit manufacture and traffic and related information
There are no published statistics (for example, country data on seizures of illicit 
CBD) available. 
6.17  Current international controls and their impact
CBD is not explicitly specified for inclusion in the schedules of the 1961 and the 
1971 United Nations International Drug Control Conventions, nor is it included 
in the List of precursors and chemicals frequently used in the illicit manufacture 
of narcotic drugs and psychotropic substances (6) under the United Nations 
Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances 
of 1988. However, if prepared as an extract or tincture of cannabis it is controlled 
in Schedule I of the Single Convention on Narcotic Drugs, 1961. 
6. Cannabidiol
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6.18  Current and past national controls
Several countries have CBD under some form of regulatory control. However, 
some have relaxed their control in recent years, in part to make CBD more 
accessible for medical use or research. 
6.19  WHO review history
A pre-review of CBD was undertaken during the thirty-ninth meeting of the 
ECDD in November 2017 following a recommendation from the thirty-eighth 
ECDD that pre-review documentation on cannabis-related substances, including 
CBD, be prepared and evaluated at a subsequent Committee meeting. Following 
its pre-review at the thirty-ninth ECDD meeting, the Committee recommended 
that extracts and preparations containing almost exclusively CBD be subject to 
critical review at the fortieth meeting of the ECDD.
6.20  Recommendation
CBD is one of the naturally occurring cannabinoids found in cannabis plants. 
There are no case reports of abuse or dependence relating to the use of pure CBD. 
No public health problems have been associated with CBD use. 
CBD has been found to be generally well tolerated and to have a good 
safety profile. Adverse effects of CBD use include loss of appetite, diarrhoea and 
fatigue. 
Therapeutic applications of CBD are being researched for a variety of 
clinical uses. Research in this area is most advanced in the treatment of epilepsy. 
In clinical trials, one pure CBD product has demonstrated effectiveness for 
treating some forms of epilepsy, such as Lennox-Gastaut syndrome and Dravet 
syndrome, which are often resistant to other forms of medication. 
CBD is not specifically listed in the schedules of the 1961, 1971 or 1988 
United Nations International Drug Control Conventions. However, if prepared 
as an extract or tincture, it is controlled under Schedule I of the 1961 Single 
Convention on Narcotic Drugs. 
There is no evidence that CBD as a substance is liable to similar abuse 
or leads to similar ill-effects to substances controlled under the 1961 or 1971 
Conventions such as cannabis or Δ9-THC, respectively.
The Committee recommended that preparations considered to be pure 
CBD should not be scheduled. 
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7. Cannabis and cannabis resin
7.1  Substance identification
7.1.1  Cannabis plant 
The flowering or fruiting tops of the cannabis plant (excluding the seeds and 
leaves when not accompanied by the tops) from which the resin has not been 
extracted. 
7.1.2  Cannabis resin
The separated resin, whether crude or purified, obtained from the cannabis plant.
7.2  Chemistry
Cannabis sativa (C. sativa) is one of the world’s oldest cultivated plants. Cannabis 
is an annual flowering plant, generally dioecious (i.e. with the male and female 
flowers on separate plants), although monoecious plants, where the male and 
female flowers are on the same plant, can also be found. To date, more than 
500 naturally occurring compounds have been identified in the cannabis plant, 
including cannabinoids (more than 100 chemicals unique to the plant), terpenoids 
and alkaloids. Cannabis contains a characteristic class of terpenophenolic 
secondary metabolites, named phytocannabinoids to distinguish them from 
synthetic and endogenous cannabinoids. To date, 120 phytocannabinoids have 
been recorded for C. sativa, and can be classified into 11 general types. Δ9-
tetrahydrocannabinol (Δ9-THC) and CBD are the most important of the plant 
cannabinoids. Δ9-THC is thought to be the principal intoxicant constituent of 
C. sativa. In plants, Δ9-THC and CBD are derived from their acidic precursors 
Δ9-tetrahydrocannabinolic acid (THCA) and CBDA, respectively. Subsequent 
decarboxylation of THCA and CBDA, via light exposure, heating or ageing, 
results in Δ9-THC or CBD. Concentrations of Δ9-THC or THCA contained in 
cannabis vary across strains and across the plant itself, with resin (i.e. hashish) 
and unfertilized female flowers (i.e. sinsemilla) having higher concentrations 
than other parts such as the leaf. Once dried, the foliage and floral material are 
stripped from the stalk and twigs, which are almost devoid of cannabinoids. The 
resinous secretions of the plant, which are produced in the glandular trichomes, 
can be collected to yield a product with a higher concentration of Δ9-THC than 
occurs in the whole plant inflorescence. In addition to the secretions, cannabis 
resin consists of finer plant material and appears as a loose or pressed sticky 
powder, depending on the method of production.
19
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7.3  Ease of convertibility into controlled substances
Not applicable.
7.4  General pharmacology
Cannabis tops and cannabis resin (i.e. hashish) are typically administered via 
inhalation after combustion (i.e. by smoking). Most of the existing research 
on the pharmacokinetics of cannabis has focused on Δ9-THC. Records from 
the United Kingdom of Great Britain and Northern Ireland and the USA show 
that average concentrations of Δ9-THC contained in cannabis plants bred for 
non-medical use have increased over time (from approximately 4% in 1995 
to approximately 12% in 2014). Some cannabis plants bred for medicinal use 
may have decreased concentrations of Δ9-THC and increased concentrations 
of CBD. Absorption of Δ9-THC in smoked cannabis is rapid, and measurable 
levels are observed in plasma within seconds after the first puff. Bioavailability 
of Δ9-THC after cannabis smoking ranges from 10 to 56%. This percentage is 
affected by dose, history of use and individual differences in physiology. It also 
depends on factors such as smoking topography and efficiency. Δ9-THC has an 
active metabolite, 11-hydroxy-Δ9-tetrahydrocannabinol (11-OH-Δ9-THC). The 
principal metabolite, 11-nor-carboxy-Δ9-THC, is inactive. 
Body fat serves as a storage reservoir for Δ9-THC, particularly in people 
who consume the drug daily or almost daily. Among such people Δ9-THC is 
eliminated slowly from fat tissues. 
The pharmacokinetics of CBD and other minor phytocannabinoids 
contained in the cannabis plant, including cannabinol, cannabigerol and 
tetrahydrocannabivarin, following smoking of cannabis, resemble the pattern 
observed with Δ9-THC.
Psychoactive effects of cannabis associated with its abuse are mediated via 
Δ9-THC interaction with the endocannabinoid system in the brain. Specifically, 
Δ9-THC is a partial agonist at CB1 receptors. Δ9-THC is also an agonist at the 
CB2 receptor, which mediates some of its peripheral effects. Cannabis/Δ9-THC 
interaction with other major neurotransmitter systems (such as dopamine, 
opioid) is mainly indirect through the interplay of these systems with the 
endocannabinoid system. The pharmacological effects of minor cannabinoids 
(for example, tetrahydrocannabivarin, cannabigerol and cannabichromene) have 
not been studied in detail.
A hypothesis that other cannabis plant constituents may interact with 
Δ9-THC and alter its effects is referred to as the “entourage effect”. So far, no clear 
scientific support for this hypothesis with regard to Δ9-THC psychoactive effects 
has been published.
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7.5  Toxicology
Most of the evidence on the toxicology of cannabis comes from observational 
population studies from which causation cannot be inferred. Cardiovascular 
effects of cannabis appear minimal or transient. Initial ingestion promotes 
tachycardia and increases blood pressure, but this subsides with tolerance and 
may even result in the opposite effects. There is limited evidence for a modestly 
increased risk of myocardial infarction associated with cannabis use. Smoking 
cannabis is linked to the typical ill-effects of smoking any substance, including 
the risk of chronic bronchitis.
Maternal cannabis users give birth to babies with birthweights that are on 
average 109 g lower than those born to mothers who do not use cannabis. There 
is limited evidence for a modest increase in the risk of birth defects. Impaired 
brain development, as demonstrated by poor connectivity, may contribute to the 
association between early, regular cannabis use and a decline in IQ, although the 
extent of these cognitive difficulties appears equivocal. Cannabis smoking has 
been reported to lead to a 2.5-fold increase in the risk of testicular cancer. 
7.6  Adverse reactions in humans
The acute consumption of cannabis can induce euphoria, laughter and 
talkativeness, change sensory and time perception, and compromise motor 
control and judgement. It can stimulate appetite and promote dry mouth and 
dizziness. Acute cannabis use impairs certain types of cognitive function and can 
interfere with attention, learning and memory. It can also precipitate a short-
lasting psychotic state in healthy individuals, which reverses once the effects 
of the drug have abated. Cannabis can impair driving skills and people driving 
under the influence of cannabis are 20–30% more likely to be involved in a car 
accident. Children who consume cannabis are at risk of possible respiratory 
depression, tachycardia and coma. 
Most of the adverse effects associated with cannabis result from chronic 
use, according to data accumulated among recreational (non-medical) users. 
Chronic regular (daily or near daily) cannabis use is particularly problematic 
for young people, whose brains continue to develop into their mid-twenties. 
A modest proportion of people who initiate cannabis use in adolescence show 
decreased IQ (by as much as 8 points when cannabis is used from the ages of 13 
to 38 years). Regular cannabis use is associated with an increased risk of anxiety, 
depression and psychotic illness, and cannabis use may worsen the course of 
these disorders. Population studies report that cannabis use leads to a twofold 
increase in the risk of schizophrenia, although the majority of cannabis users 
will not develop a psychotic disorder and those who do are likely to have some 
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genetic vulnerability to cannabis-induced psychosis. Regular cannabis use may 
be associated with poor school performance, lower income, increased likelihood 
of requiring socioeconomic assistance, unemployment, criminal behaviour and 
decreased satisfaction with life.
7.7  Dependence potential
The number of studies investigating physical dependence potential in laboratory 
animals is limited. When exposed to cannabis smoke, mice and rats can be made 
physically dependent, and withdrawal effects can be reversed by intravenous 
administration of Δ9-THC. However, rhesus monkeys exposed to cannabis 
smoke once daily or twice weekly for one year did not show behavioural signs of 
withdrawal upon abrupt termination. 
Human users of cannabis can become physically dependent, and clinical 
diagnostic manuals such as the Diagnostic and Statistical Manual of Mental 
Disorders, fifth edition (DSM-5) and the International Classification of Diseases, 
tenth revision (ICD-10) recognize the existence of a cannabis use disorder. It is 
estimated that the percentage of regular cannabis users who have experienced at 
least one episode of cannabis withdrawal during abstinence ranges from 16 to 
33%. The onset of withdrawal typically occurs within 24 to 48 hours of abstinence 
following a period of regular use, with peak intensity usually occurring 2 to 6 days 
after last use. The withdrawal syndrome may include mood changes, irritability, 
increased anger, anxiety, craving, restlessness, sleep impairment, stomach pain 
and decreased appetite. 
7.8  Abuse potential
Preclinical research on cannabis smoke has been limited. Mice exposed to cannabis 
smoke show typical effects of Δ9-THC including catalepsy, antinociception, 
hypothermia and hypolocomotion, and these effects can be antagonized by the 
CB1 receptor antagonist, rimonabant. 
In humans, self-reported subjective effects associated with smoked 
cannabis in laboratory studies include dose-dependent increases in ratings 
of “drug effect”, “high” or “stoned”. The reinforcing effects of smoked cannabis 
have been demonstrated in several laboratory-based self-administration studies 
with smoked cannabis being readily self-administered by experienced users. 
Similar effects are produced by Δ9-THC alone when administered orally or when 
smoked. Increases in the intensity of self-reported subjective effects of cannabis 
(for example, “high” or “stoned”) are associated with increasing concentrations 
of Δ9-THC. 
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7.9  Therapeutic applications, extent of therapeutic use and 
epidemiology of medical use
Several countries have laws on medicinal cannabis in effect. An international 
survey of 953 medicinal cannabis users from 31 countries found that most of 
them were current users under the care of a health professional and had been 
using cannabis-based medications for several years. The five medical conditions 
for which cannabis and cannabis-based medications were most often used as a 
treatment in this survey were back pain, sleep disorders, depression, post-injury 
pain and multiple sclerosis.
Research on the potential medical applications of cannabis is ongoing. The 
results of randomized controlled trials (RCTs) show that smoked cannabis can 
enhance weight gain in HIV patients (1 RCT) and treat neuropathic pain (3 RCTs). 
Inhaled aerosolized cannabis leads to dose-dependent reductions in spontaneous 
pain ratings among patients with treatment-refractory pain due to diabetic 
peripheral neuropathy. Two open-label, uncontrolled, observational studies of 
smoked cannabis or vaporized cannabis reported significantly decreased motor 
disability and pain scores in patients with Parkinson’s disease. 
7.10  Listing on the WHO Model List of Essential Medicines
Cannabis plant and cannabis resin are not included in the WHO EML (20th list) 
or the WHO Model List of Essential Medicines for Children (6th list).
7.11  Marketing authorizations (as a medicinal product)
Bedrocan Cannabis has been granted marketing authorization in the Netherlands 
to produce five standardized plant varieties (whole dried flower) that are available 
to patients under direct physician care. Cannabis for both medicinal and research 
use is available in several countries. 
7.12  Industrial use
Low potency (0.2–0.3% Δ9-THC) cannabis plants (hemp) are cultivated to 
produce paper, textiles, rope or twine, and construction materials based on fibre 
from stalks. Grain from industrial hemp is used in food products, cosmetics, 
plastics and fuel. Cannabis plants grown for these purposes are excluded from 
control under the 1961 Convention.
7.13  Non-medical use, abuse and dependence
Non-medical cannabis use is global, with an estimated prevalence of 3.8% in 2015, 
which means more than 183 million adults used cannabis in that year. Prevalence 
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can vary widely across countries, from less than 1% to over 38%. The estimates of 
the risk of developing cannabis use disorder among users vary among studies and 
countries, but it appears that 1 in 10 or 1 in 11 is a representative figure. 
7.14  Nature and magnitude of public health problems related to 
misuse, abuse and dependence
The global burden of disease attributable to cannabis use disorder, expressed in 
disability-adjusted life years (DALYs) (one DALY represents one year of life lost 
either due to premature mortality or due to living with disability) was 646 480 
DALYs in 2016. Driving under the influence of cannabis increases the risk of 
accidents and is therefore a public health threat. 
7.15  Licit production, consumption and international trade
This is addressed under Section 7.11 (Marketing authorizations (as a medicinal 
product)).
7.16  Illicit manufacture and traffic and related information
Cannabis is the most widely illicitly produced drug worldwide, cultivated in at 
least 135 countries covering 92% of the global population. Cannabis seizures 
made up 53% of all drug seizures worldwide in 2015. 
7.17  Current international controls and their impact
Cannabis, cannabis resin, extracts and tinctures of cannabis are grouped together 
in Schedule I of the 1961 United Nations Single Convention on Narcotic Drugs. 
Cannabis plants and resin are also under Schedule IV of this Convention, which 
contains substances that are particularly liable to abuse and to produce ill-effects 
and do not have therapeutic advantages that offset these effects.
7.18  Current and past national controls
Cannabis, including plants and resin, is controlled in most WHO Member States. 
A growing number of countries, however, have endorsed regulations enabling 
the medical use of cannabis plants to relieve the symptoms of specific medical 
conditions. The European Medicines Agency has stated that the use of cannabis 
as medicine must follow the laws of each member. 
7.19  WHO review history
Cannabis and cannabis resin have not previously been formally reviewed by the 
ECDD. 
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7.20  Recommendation
Cannabis is defined as the flowering tops or separated resin of the C. sativa plant. 
Cannabis contains 121 reported phytocannabinoids, the most prominent being 
Δ9-THC and CBD. Δ9-THC is thought to be the principal intoxicant constituent 
of cannabis. 
When used acutely, cannabis causes adverse effects such as dizziness and 
impairment of motor control and cognitive function. Cannabis use can impair 
driving. There are particular risks reported for children, such as respiratory 
depression, tachycardia and coma. The adverse effects of cannabis consumption 
are similar to those produced by Δ9-THC alone.
Most of the adverse effects associated with cannabis result from chronic 
use. Regular cannabis use is associated with increased risk of mental health 
disorders such as anxiety, depression and psychotic illness. Chronic regular 
cannabis use is particularly problematic for young people as a result of its effects 
on the developing brain. 
Cannabis can cause physical dependence in humans as evidenced by the 
onset of cannabis withdrawal symptoms upon abstinence. Withdrawal symptoms 
include mood changes, irritability and sleep impairment. Clinical diagnostic 
guidelines such as DSM-5 and ICD-10 recognize cannabis use disorder.
The Committee considered information regarding the therapeutic 
indications of cannabis and ongoing research into its possible medical 
applications. Several countries permit the use of cannabis for the treatment of 
medical conditions such as back pain, sleep disorders, depression, post-injury 
pain and multiple sclerosis. 
Cannabis plant and cannabis resin are included in Schedule I and Schedule 
IV of the 1961 Single Convention on Narcotic Drugs. Substances that are included 
in both these schedules are particularly liable to abuse and to produce ill-effects. 
Other substances that are included in both Schedules I and IV are fentanyl 
analogues and other opioids that are considered especially dangerous. 
The evidence presented to the Committee did not indicate that cannabis 
plant and cannabis resin were liable to produce ill-effects similar to the other 
substances in Schedule IV of the 1961 Convention on Narcotic Drugs. The 
inclusion of cannabis and cannabis resin in Schedule IV may not be consistent 
with the criteria for inclusion in Schedule IV. 
The Committee concluded that there is sufficient evidence to recommend 
a critical review of cannabis plant and cannabis resin at a future ECDD meeting 
and to explore further the appropriateness of their current scheduling within the 
1961 Convention. 
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8. Extracts and tinctures of cannabis
8.1  Substance identification
Extracts and tinctures of cannabis are preparations that have been extracted 
from the leaves and flowers of C. sativa. They include oils, rosin, distillates and 
pharmaceutical products containing a mixture of Δ9-THC and CBD. 
8.2  Chemistry
8.2.1  Cannabis extracts
There are several methods for preparing the different cannabis extracts (i.e. 
extract mixtures from the leaves and flowers of C. sativa). These include:
 ■ Supercritical carbon dioxide (CO2) extraction
  Cannabis inflorescence is treated with supercritical CO2, which is 
highly pressurized liquid CO2. The extract is separated from the CO2 
that is recovered and passed back through the cannabis inflorescence 
several times until the extraction process is complete. The most sig-
nificant advantage of CO2 extraction is that it leaves no harmful resi-
dues in the resulting product.
 ■ Butane hash oil (BHO)
  BHO is a resinous, nonpolar extract of cannabis inflorescence made 
using butane as a solvent, which is eventually purged under vacuum 
at room temperature. The final extract can contain from 50 to 90% of 
the active ingredient, either (−)-trans-delta-9-tetrahydrocannabinol 
(Δ9- THC) or CBD. The terpene content ranges from 0.1 to 34%, but 
this can be increased by dipping BHO in a vial of terpenes prior to 
use (“terpene dipping”). 
 ■ Propane hash oil (PHO)
  PHO is similar to BHO, but it uses propane as the solvent.
 ■ Rosin
  The rosin method exploits heat and pressure to squeeze a resinous 
product from the plant material. Industrial-sized presses capable 
of processing large amounts of hashish oil within seconds are 
available. As no solvent is used in the process, it is not an extract or 
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tincture according to the usual definitions, but is included here for 
completeness.
 ■ Distillates
  Distillates are concentrated extracts of cannabis inflorescence 
through which a specific solvent passes and collects cannabinoids 
and terpenes.
 ■ Other organic extracts
  Other hydrocarbon solvents that can be employed for cannabis 
extraction include chloroform and hexane. Oils such as olive oil or 
sesame oil may also be used.
8.2.2  Tinctures of cannabis
The tinctures of cannabis are extracts of the flowering tops or other parts of C. 
sativa where alcohol (ethanol) is used as the solvent. Ethanol is a very effective 
solvent for the extraction of most of the substances contained in cannabis 
inflorescences. It has a high extraction efficiency and is more effective than water 
and hydrocarbon solvents (for example, hexane).
 ■ Cannabis oils
  Cannabis oils may contain Δ9-THC and other cannabinoids obtained 
using a method of extraction as described above. However, some oils, 
such as essential oil and hemp seed oil, do not contain significant 
concentrations of Δ9-THC. Medicinal cannabis oil is an extraction of 
C. sativa typically made with olive oil or sesame oil, which is used in 
pharmacy for the preparation of medicinal extracts.
 ■ Aqueous extracts
  An aqueous extract of C. sativa is often referred to as a tea. The use 
of boiling water is a simple and probably one of the oldest methods 
for preparing a cannabis extract for oral administration. The amount 
of Δ9-THC extracted using this method is only a fraction of that 
obtainable using other extraction methods. To compensate for the 
low solubility of Δ9-THC in water, users of tea often add a small 
amount of vegetable oil or butter and increase boiling time.
 ■ CBD in preparations with other cannabis-related ingredients.
  Sativex® is a pharmaceutical formulation manufactured in the United 
Kingdom of Great Britain and Northern Ireland by incorporating 
purified botanically derived drug substances containing an accurately 
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measured 1:1 ratio of Δ9-THC and CBD into a final product containing 
ethanol, propylene glycol and peppermint oil as excipients. Sativex® 
is in the form of an oromucosal spray approved for treating spasticity 
in patients with multiple sclerosis. Each 0.1 mL spray contains 2.7 
mg of Δ9-THC and 2.5 mg of CBD. Two cannabis plant strains are 
grown under regulated glasshouse conditions, principally producing 
Δ9-THC and CBD. The dried plant material, including the foliage and 
inflorescence, is uniformly heated to decarboxylate the precursors, 
THCA and CBDA, to Δ9-THC and CBD, respectively. The plant 
material is then extracted by supercritical liquid CO2 extraction to 
obtain the two soft extracts with trade names Tetranabinex (>90% 
Δ9-THC) and Nabidiolex (>85% CBD).
  One or more of a variety of methods can be used for detection of the 
presence of cannabinoids in these substances. These methods include 
colour tests, thin-layer chromatography, gas chromatography, liquid 
chromatography, nuclear magnetic resonance and immunoassay.
8.3  Ease of convertibility into controlled substances
Not applicable.
8.4  General pharmacology
In humans, cannabis extracts may be delivered through various routes of 
administration, including sublingual, oral, inhalation (smoking or vaping), rectal 
and transdermal. “Dosage” of cannabis extracts most often refers to the amount 
of Δ9-THC contained in the preparation. Tinctures are usually administered 
sublingually or used to infuse edibles or beverages (i.e. oral administration). Oils 
may be incorporated into food or beverages for oral administration or may be 
vaped or “dabbed”. Sativex® is formulated into an oromucosal spray. 
In the few studies that have been done, pharmacokinetic profiles of vaped 
versus smoked cannabis/cannabis extracts appear to be similar. Absorption of 
Δ9-THC from inhalation is rapid and measurable levels are observed in plasma 
within seconds after the first puff. While peak plasma levels typically occur within 
3–10 minutes after smoking, peak “highs” do not occur until 20–30 minutes 
after smoking. Absorption of Δ9-THC following oral ingestion is slower and 
maximal plasma levels are lower, typically resulting in flatter concentration–time 
curves. The pharmacokinetics of CBD and Δ9-THC in Sativex® are similar. The 
metabolism of Δ9-THC and CBD is described elsewhere in this report.
To date, more than 500 naturally occurring compounds have been 
identified in cannabis, including cannabinoids (more than 100 chemicals unique 
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to the plant), terpenoids and alkaloids. However, except for Δ9-THC and CBD 
(in some plants), most of these compounds are present in the plant in relatively 
small quantities. In addition, the extraction process is designed to concentrate 
the desired constituents (usually Δ9-THC and/or CBD). Hence, the degree to 
which other compounds may contribute to the array of pharmacological and 
behavioural effects produced by cannabis extracts is largely unknown. However, 
because many extracts that may be used for smoking or vapour inhalation 
contain high concentrations of THC, there is the potential for relatively strong 
and immediate effects of Δ9-THC. 
8.5  Toxicology
Little information is available on the toxicology of cannabis extracts, tinctures, 
oils and tea. The toxicity produced by Δ9-THC-rich cannabis extracts, tinctures, 
oils and tea are similar to those observed with Δ9-THC, but, as noted above, the 
effects may be more pronounced with greater risk of adverse effects when extracts 
with high Δ9-THC concentrations are inhaled.
Depending on the method used, cannabis extract may contain residual 
solvents (naphtha, isopropanol, acetone, hexane, ethyl alcohol or butane) that are 
harmful if ingested by the user. Some are found to contain contaminants such as 
pesticides. Thinning agents such as propylene glycol and polyethylene glycol 400 
(used to allow smooth flow of viscous cannabis oils from cartridges) can produce 
high concentrations of toxic acetaldehyde and formaldehyde when heated in 
certain devices. In addition, terpenes can be converted to the toxic degradants 
methacrolein (an irritant) and benzene (a carcinogen). 
Sativex® appears not to be mutagenic, carcinogenic or teratogenic.
8.6  Adverse reactions in humans
Adverse reactions to Δ9-THC-rich cannabis extracts, tinctures, oils and tea are 
similar to those observed with Δ9-THC, but, as noted above, the effects may be 
more pronounced with greater risk of adverse effects when extracts with high Δ9-
THC concentrations are inhaled.
Common adverse effects of Sativex® are mild to moderate dizziness and 
fatigue. Other common side-effects are nausea and vomiting, hypotension, 
somnolence, disturbance of attention, confusion, asthenia (weakness), dry 
mouth, diarrhoea, anxiety and headache. Transient adverse effects such as 
increased heart rate and blood pressure, disorientation, depression, euphoria, 
transient psychotic reactions and dissociation have also been reported. In rare 
instances, oromucosal sprays may cause pain, discomfort, distorted taste, mouth 
ulceration and glossodynia (burning sensation in the mouth and tongue). There 
are no reported cases of driving under the influence of Sativex®. 
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8.7  Dependence potential
There are no published scientific studies that have evaluated the dependence 
potential of pure cannabis extracts or Sativex® in laboratory animals. However, the 
psychoactive constituent, Δ9-THC, present in most extracts, has been separately 
examined and shown to have dependence potential. Frequent BHO use among 
cannabis users has been associated with physical dependence and perceived 
impaired control over cannabis use. 
The dependence potential of Sativex® has not been evaluated in humans. 
However, there is limited evidence of a withdrawal syndrome associated with 
Sativex® treatment. When a mistake in a trial led to a 2-week period of abstinence, 
44% of participants experienced one or more signs associated with withdrawal 
(for example, sleep disruption, appetite changes, mood changes or vivid dreams).
8.8  Abuse potential
There are few published reports of studies that have evaluated the abuse potential 
of cannabis extracts in animals. When injected and when inhaled via modified 
e-cigarette apparatus, cannabis extract produced Δ9-THC-like behavioural effects 
in rodents. In one study, when cannabis extract was inhaled via a vaporizer, it 
produced place preference in a conditioned place preference procedure. There is 
evidence from animal studies indicating the abuse potential of Δ9-THC as a pure 
substance whereas CBD does not have abuse potential. 
Vaping and smoking routes are known to produce rapid psychoactive effects. 
However, the abuse potential of high-potency cannabis extracts administered via 
vaporizing has not been studied in humans. In drug-naive healthy volunteers, an 
orally administered cannabis extract containing a 2:1 ratio of Δ9-THC to CBD 
induced fatigue, drowsiness, dizziness and feeling “high”. 
A clinical trial to evaluate the abuse potential of Sativex® in recreational 
cannabis users showed that high doses (21.6 or 43.2 mg) of Δ9-THC induced 
cannabis-like effects, but this did not occur at a lower dose. Abuse has not been 
reported in post-market surveillance of Sativex®. However, euphoria has been 
reported as an adverse effect of Sativex®.
8.9  Therapeutic applications, extent of therapeutic use and 
epidemiology of medical use
Sativex® is being investigated for a variety of indications including, but not 
limited to, treatment of spasticity due to multiple sclerosis, chronic pain, anxiety 
disorder, cannabis use disorder, attention-deficit/hyperactivity disorder, and 
depression and sleep disorders.
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8.10  Listing on the WHO Model List of Essential Medicines
Cannabis extracts and tinctures are not listed on the WHO EML (20th list) or the 
WHO Model List of Essential Medicines for Children (6th list).
8.11  Marketing authorizations (as a medicinal product)
Sativex® has been granted marketing authorization for treatment of spasticity due 
to multiple sclerosis in at least 20 countries. 
8.12  Industrial use
Cannabis extracts and tinctures have no known industrial uses. 
8.13  Non-medical use, abuse and dependence
Worldwide, cannabis is mainly used in the forms of herbs and resins for 
recreational (non-medical) purposes or self-medication; extracts and tinctures 
are thought to play a smaller role.
A global online survey in several countries reported that 7% of the past-
year cannabis users had used BHO. Two surveys conducted in the USA found 
rates of vaporization of cannabis oil and wax of 15.5% and 10.2% among lifetime 
cannabis users and 22.9% and 14.8% among those with lifetime e-cigarette use, 
respectively. An additional study in the USA found that among past-year cannabis 
users, 44% (n = 121) had used BHO in the previous 12 months and that frequent 
BHO use was associated with higher levels of physical dependence. There are no 
reports of misuse of pharmaceutical products containing a mixture of Δ9-THC 
and CBD.
8.14  Nature and magnitude of public health problems related to 
misuse, abuse and dependence
The public health problems related to the use of cannabis extracts and tinctures 
are difficult to assess, in part because existing reports rarely specify the form of 
cannabis used. There is some evidence linking the use of butane cannabis oil 
to dependence. The risk of burns has been reported during the preparation of 
extracts where solvents are used. 
8.15  Licit production, consumption and international trade
Licit production is important for medical research into the therapeutic potential 
of cannabis preparations. 
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8.16  Illicit manufacture and traffic and related information
There is evidence of the illicit marketing of cannabis extracts and tinctures for 
recreational (non-medical) uses through online pharmacies. Cannabis extracts 
are extensively described on Internet forums and are offered for sale via the 
Internet. 
8.17 Current international controls and their impact
Cannabis extracts and tinctures of cannabis are listed in Schedule I of the Single 
Convention on Narcotic Drugs, 1961.
8.18  Current and past national controls
Cannabis, including its extracts and tinctures, is controlled in most Member 
States. A growing number of countries, however, have adopted regulations that 
enable the medical use of cannabis extracts and tinctures to relieve the symptoms 
of specific medical conditions.
8.19  WHO review history
Cannabis extracts and tinctures have never been formally reviewed by the ECDD. 
8.20  Recommendation
Extracts and tinctures of cannabis are substances that have been extracted 
from the C. sativa plant. They include cannabis oils, teas and an extract with 
approximately equal quantities of Δ9-THC and CBD. These substances can be 
administered through various routes including orally and by smoke inhalation.
Evidence on the dependence potential of extracts and tinctures of 
cannabis varies by substance. There are no published studies that have evaluated 
the dependence potential of mixtures of Δ9-THC and CBD, but there is limited 
evidence of a withdrawal syndrome upon abrupt cessation (for example, sleep 
disruption and mood changes). Frequent use of the BHO extract has been 
associated with physical dependence. The psychoactive constituent, Δ9-THC, 
present in most extracts has been separately studied and has been shown to have 
dependence potential. 
Few published studies have evaluated the abuse potential of cannabis 
extracts in animals or humans. There are, however, studies that have investigated 
the abuse potential of various components of extracts and tinctures of cannabis. 
While particular components, such as Δ9-THC, have demonstrated abuse 
potential, other components in these preparations, such as CBD, have not.
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The Committee recognized that the term “extracts and tinctures” as cited 
in the 1961 Single Convention on Narcotic Drugs encompasses preparations 
that have psychoactive properties as well as those that do not. The Committee 
also recognized that the psychoactive properties of these preparations are due 
principally to Δ9-THC, which is currently scheduled in the 1971 Convention on 
Psychotropic Substances. Among the substances that are not psychoactive in the 
preparations that are derived as extracts or tinctures of cannabis are some that 
have promising therapeutic indications, such as CBD. 
Cannabis extracts and tinctures are placed in Schedule I of the 1961 Single 
Convention on Narcotic Drugs. The Committee noted that the category “extract 
and tinctures of cannabis” encompasses very diverse formulations with varying 
ratios of cannabis components, in particular Δ9-THC, and with or without 
psychoactive properties. 
The Committee therefore concluded that there is sufficient information 
to recommend a critical review of extracts and tinctures of cannabis at a future 
ECDD meeting to address the necessity of continuing to include the term “extracts 
and tinctures of cannabis” in the 1961 Convention. 
33
9. Delta-9-tetrahydrocannabinol
9. Delta-9-tetrahydrocannabinol (Δ9-THC; dronabinol) 
9.1  Substance identification
Delta-9-tetrahydrocannabinol (Δ9-THC; dronabinol) refers to the following four 
stereoisomers:
 a. (−)-trans-Δ9-tetrahydrocannabinol (also known as dronabinol)
 b. (+)-trans-Δ9-tetrahydrocannabinol
 c. (−)-cis-Δ9-tetrahydrocannabinol
 d. (+)-cis- Δ9-tetrahydrocannabinol
The stereoisomer (−)-trans-Δ9-THC is the only one that occurs naturally in the 
cannabis plant and is generally the only stereoisomer that has been studied. 
Dronabinol is the International Nonproprietary Name (INN) for this isomer. 
Where the term “Δ9-THC” is used in this report without further specification, 
it refers to (−)-trans-Δ9-THC or dronabinol. If reference is made to a different 
isomer, this is explicitly specified. 
9.2  Chemistry
(−)-Trans-Δ9-THC does not occur at a significant concentration in cannabis 
plants. The plant synthesizes primarily the carboxylic acid form of (−)-trans-Δ9-
THC, namely, Δ9-tetrahydrocannabinolic acid (THCA) from cannabigerolic acid 
and this substance accumulates in the glandular trichomes of flowers and leaves. 
THCA is thermally unstable and can be quickly decarboxylated to (−)-trans-
Δ9-THC when exposed to heat via smoking or baking; this conversion can also 
occur spontaneously during storage. (−)-Trans-Δ9-THC can be extracted from 
the plant after it has been heated; THCA can be extracted from the plant and 
then converted to (−)-trans-Δ9-THC; or it can be synthesized from terpene and 
olivetol.
Synthetic methods for the other isomers have been reported.
Several analytical methods are available for the measurement of (−)-trans-
Δ9-THC in different matrices such as cannabis plant, cannabis extracts and 
biological fluids. These are mostly chromatographic methods coupled to detection 
techniques such as ultraviolet and mass spectrometry.
9.3  Ease of convertibility into controlled substances
The only controlled substance that (−)-trans-Δ9-THC can be converted into is its 
isomer (−)-trans- Δ8-THC, which is in Schedule I of the 1971 Convention.
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9.4  General pharmacology
Δ9-THC is highly lipophilic and animal studies have found that it is readily 
absorbed and distributed to the brain and other organs following various 
routes of administration. These include the intraperitoneal, oral, intramuscular, 
intravenous and inhalation routes. In humans, the predominant route of 
administration of pure Δ9-THC is oral. The stereochemical variants of Δ9-THC 
are not routinely administered. 
Compared to absorption of Δ9-THC in smoked cannabis, maximal 
plasma levels after oral administration are lower, typically resulting in flatter 
concentration–time curves. Peak plasma levels usually occur 60–120 minutes after 
ingestion although delays of up to 4–6 hours have also been reported. Estimated 
bioavailability averages 6%, with considerable variability among individuals. 
Ingestion is accompanied by significant first-pass metabolism in the liver, further 
decreasing the amount of Δ9-THC that reaches sites of action. Δ9-THC is strongly 
bound to plasma proteins and is readily distributed to highly vascularized tissues 
(for example, the liver, heart and lungs) after absorption. 
Metabolism of orally administered Δ9-THC occurs primarily in the liver 
and is extensive, with almost 100 metabolites having been identified. 11-hydroxy-
Δ9-tetrahydrocannabinol (11-OH-Δ9-THC) is an active metabolite. Owing to 
its extensive metabolism, relatively little Δ9-THC is eliminated from the body 
unchanged. Δ9-THC is excreted primarily in the faeces (65–80%) and in the urine 
(20–35%).
When administered to animals, Δ9-THC produces a characteristic profile 
of pharmacological effects. These include:
 ■ a tetrad of effects – locomotor suppression, antinociception, hypo-
thermia and catalepsy – in mice and rats; 
 ■ discriminative stimulus effects in rats, mice, pigeons and rhesus 
monkeys; 
 ■ reinforcing effects in squirrel monkeys; and 
 ■ static ataxia in dogs. 
These cannabimimetic effects are produced through interaction with an 
endogenous cannabinoid system that includes two cannabinoid receptors, CB1 
and CB2. CB1 receptors are widespread and abundant in the brain and periphery, 
CB2 receptors are confined primarily to the periphery. The psychoactive effects of 
Δ9-THC are mediated via activation of CB1 receptors in the brain.
The limited information on the pharmacology of the stereochemical 
variants of (–)-trans-Δ9-THC suggests that they have little activity. (–)-Trans-Δ9-
THC was at least tenfold more potent in the dog static ataxia model than (+)-cis-
Δ9-THC or (+)-trans-Δ9-THC, neither of which produced the full syndrome of 
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cannabinoid effects at the highest dose administered. In addition, (–)-trans-Δ9-
THC exhibited a tenfold greater hypothermic effect in mice and was 100-fold 
more potent at decreasing schedule-controlled responding in rhesus monkeys 
than (+)-Δ9-THC.
9.5  Toxicology
Δ9-THC has very low potential to produce lethal effects. Following oral 
administration, the median lethal dose (LD50) is 800 mg/kg in rats, up to 
3000 mg/kg in dogs and up to 9000 mg/kg in monkeys. It has been calculated 
that a lethal dose for a 70-kg human would be approximately 4 g and that such 
a dose would not typically be achieved in a human following oral consumption, 
smoking or vaporizing the substance.
Acute Δ9-THC exposure in humans produces tachycardia with an average 
increase in heart rate of eight beats per minute. Tolerance may occur to these 
effects, and decreases in blood pressure and heart rate may occur with subsequent 
exposures. Δ9-THC is a bronchodilator. In vitro and in vivo animal studies 
demonstrate that high doses of Δ9-THC can modulate the immune system in 
complex ways. In two human studies using low-dose Δ9-THC no significant 
effects on the immune system were observed.
According to a comprehensive assessment by the US National Toxicology 
Program, Δ9-THC does not have mutagenic or carcinogenic effects. Oral 
administration of Δ9-THC to rats for 77 days reduced the size of the seminal 
vesicles, seminal fluid volume, spermatogenesis and the number of Leydig cells 
in the testis. However, sperm count, mating success and testosterone levels were 
not affected. No data are available on teratogenicity in humans. In animal studies, 
administration of Δ9-THC during gestation promotes a slight decrease in fetal 
weight. It crosses the placental barrier and is secreted in the mother’s milk. 
In a randomized controlled trial with 329 multiple sclerosis patients, 
following daily administration of Δ9-THC at doses of up to 28 mg/day for three 
years, low to moderate toxicity and a low incidence of other adverse effects were 
reported. There were no differences in the median number of adverse events 
between the placebo and Δ9-THC-treated groups. Δ9-THC-treated patients 
experienced more dizziness and light-headedness as well as dissociative thinking 
and perception disorders.
9.6  Adverse reactions in humans
In humans, Δ9-THC has very similar pharmacological and subjective effects to 
those of cannabis. Users may exhibit euphoria, laughter and increased loquacity. 
Δ9-THC increases appetite, promotes dry mouth and occasional dizziness, and 
produces apparent enhancement of visual, olfactory and auditory perceptions. 
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Exposure to Δ9-THC may also cause nausea and vomiting in some users. 
Following repeated exposure, users generally develop tolerance to the effects of 
Δ9 THC. Δ9-THC exposure can cause subtle cognitive deficits such as impairment 
of attention and short-term memory. Higher doses of Δ9-THC are associated 
with anxiety, panic, confusion and disorientation in some users. Δ9-THC can 
also provoke transient psychosis-like psychological phenomena in some healthy 
participants. 
Oral Δ9-THC is reported to cause impairment of driving skills in both 
driving simulators and on roads. Doses of 10 and 20 mg of Δ9-THC increased 
standard deviation of lateral position – indicative of loss of road tracking control 
– and time taken to adapt speed – indicative of increased reaction times. 
9.7  Dependence potential
Rapid and profound tolerance develops to numerous acute effects of Δ9-THC 
following chronic administration to animals. Chronic administration of Δ9-
THC can induce physical dependence in laboratory animals as evidenced by 
withdrawal effects that can emerge spontaneously or be precipitated by the 
cannabinoid receptor antagonist, rimonabant.
Two studies in humans have demonstrated the development of tolerance 
to the self-reported effects of Δ9-THC. These studies also reported withdrawal 
effects indicative of physical dependence. The symptoms of withdrawal that were 
observed included hyperactivity, increased salivation, irritability, marked changes 
in sleep patterns and restlessness. In one study, sleep disruption was found to 
persist for up to seven nights. Most withdrawal symptoms were alleviated within 
96 hours or immediately if participants re-administered Δ9-THC.
9.8  Abuse potential
One laboratory reported the successful intravenous self-administration 
of Δ9-THC in squirrel monkeys, the rates of which were attenuated by the 
administration of rimonabant. Several other laboratories have failed to establish 
the self-administration of Δ9-THC in animals. 
Δ9-THC has clear discriminative effects in several species, including 
rats, rhesus monkeys, mice and pigeons. Δ9-THC-like discriminative effects 
are produced by other cannabinoids or cannabis preparations that have been 
reported to be cannabis-like in humans, including Δ8-THC, cannabinol, hashish, 
CP55,940, WIN55,212-2, and an array of abused synthetic cannabinoids (for 
example, JWH-018, XLR-11, UR-144, AB-CHMINACA). CBD, however, does 
not produce such effects. 
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Oral administration of Δ9-THC produces subjective effects that resemble 
those of cannabis. Humans readily distinguish the effects of oral Δ9-THC as being 
cannabis-like and as different from alcohol or d-amphetamine. Furthermore, 
when orally administered or smoked Δ9-THC is compared directly to cannabis 
administered via the same route, both Δ9-THC and cannabis produce a similar 
profile of subjective effects including increased feelings of “drug effect”, experience 
of a “drug high” and increased ratings of cannabis-like effects.
In controlled laboratory settings, oral self-administration of Δ9-THC has 
been demonstrated; however, results suggest that it is a weak reinforcer at best. A 
multi-method review revealed little evidence that oral Δ9-THC is used for non-
medical purposes.
9.9  Therapeutic applications and extent of therapeutic use and 
epidemiology of medical use
Δ9-THC or dronabinol has approval in a number of countries for indications 
including anorexia associated with weight loss in patients with acquired 
immunodeficiency syndrome (AIDS) and for nausea and vomiting associated 
with cancer chemotherapy in patients who do not gain adequate relief from 
conventional antiemetic treatment. 
Δ9-THC has been explored for other indications. For example, it has 
demonstrated at least partial effectiveness in decreasing neuropathic pain, 
reducing anxiety in patients with chronic pain, increasing weight gain in 
patients with anorexia nervosa, decreasing pain intensity and increasing patient 
satisfaction when given as an adjunct to opioids for chronic pain, reducing 
spasticity in patients with multiple sclerosis, and for improving tics (or a trend 
towards such improvement) in patients with Tourette syndrome.
9.10  Listing on the WHO Model List of Essential Medicines
Δ9-THC (dronabinol) is not listed on the WHO EML (20th list) or the WHO 
Model List of Essential Medicines for Children (6th list).
9.11  Marketing authorizations (as a medicinal product)
Dronabinol (Marinol®) is supplied as round, soft gelatine capsules for oral use 
(AbbVie, Inc.), and Syndros is supplied as an oral solution (INSYS Therapeutics, 
Inc.).
9.12  Industrial use
Δ9-THC has no legitimate industrial uses.
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9.13  Non-medical use, abuse and dependence
Δ9-THC does not appear to be abused. A multi-method review revealed 
little evidence that its oral formulation was used for non-medical purposes. 
Phenomena such as “doctor-shopping” or “script-chasing” (i.e. obtaining multiple 
prescriptions from multiple doctors for the same substance) are not common. 
9.14  Nature and magnitude of public health problems related to 
misuse, abuse and dependence
Δ9-THC does not appear to have caused a public health problem related to misuse, 
abuse or dependence. See section 9.13.
9.15  Licit production, consumption and international trade
Licit production and trade occur with the medicinal products mentioned in 9.11 
(Marketing authorizations).
9.16  Illicit manufacture and traffic and related information
There are no data on the illicit manufacture of pure Δ9-THC.
9.17  Current international controls and their impact
Dronabinol, the INN of (−)-trans-Δ9-THC, and its stereochemical variants are 
included in Schedule II of the Convention on Psychotropic Substances of 1971.
9.18  Current and past national controls
Dronabinol is presumed to be controlled in all WHO Member States, except 
Uruguay where the production, sale and use of cannabis for medical or non-
medical purposes was legalized in 2016.
9.19  WHO review history
Δ9-Tetrahydrocannabinol (Δ9-THC) and its stereochemical variants, with one 
variant being dronabinol ((−)-trans-Δ9-THC), are currently listed in Schedule 
II of the 1971 Convention on Psychotropic Substances. Δ9-THC was originally 
included in Schedule I of the 1971 Convention at the time of its adoption, together 
with its stereochemical variants.
 ■ In 1989, the WHO ECDD recommended, based on the critical review 
of dronabinol ((−)-trans-Δ9-THC) undertaken at its twenty-sixth 
meeting in 1988, that dronabinol be moved to Schedule II while 
keeping the other isomers and stereochemical variants in Schedule I. 
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WHO’s proposal to transfer dronabinol to Schedule II was rejected by 
the CND at its eleventh special session in 1990.
 ■ At its twenty-seventh meeting in 1990, the ECDD carried out a critical 
review of updated information on Δ9-THC. It recommended that 
Δ9-THC and stereochemical variants be rescheduled from Schedule 
I to Schedule II of the 1971 Convention. This was done to avoid a 
distinction between Δ9-THC and its stereochemical variants leading 
to their placement under different schedules and to prevent potential 
legal and forensic analytical problems. This recommendation was 
adopted by the CND at its thirty-fourth session in 1991.
 ■ At the thirty-third ECDD meeting in 2002, Δ9-THC was again 
critically reviewed. The Committee recommended that dronabinol 
and its stereochemical variants be rescheduled from Schedule II to 
Schedule IV of the 1971 Convention. However, no further procedural 
steps were taken, i.e. there was no formal communication of this 
recommendation from WHO to the CND.
 ■ At its thirty-fourth meeting in 2006, the ECDD carried out an 
assessment of an updated critical review report on dronabinol. 
The Committee concluded that although dronabinol constitutes 
a substantial risk to public health, this risk is different from those 
related to cannabis – controlled under the 1961 Convention. The 
substance was found to have moderate therapeutic usefulness, with 
a likelihood of an increase in its medical use in light of continuing 
clinical research. Therefore, the Committee recommended that 
dronabinol and its stereochemical variants be rescheduled from 
Schedule II to Schedule III of the 1971 Convention.
 ■ In March 2007, at its fiftieth session, the CND decided by consensus 
not to vote on the recommendation of the WHO ECDD to transfer 
dronabinol and its stereochemical variants from Schedule II to 
Schedule III of the 1971 Convention. Furthermore, the CND requested 
WHO, in consultation with the INCB, as appropriate, to undertake, 
for consideration by the Commission, a review of dronabinol and 
its stereochemical variants when additional information became 
available (CND Decision 50/2). 
 ■ At its thirty-fifth meeting in 2012, the ECDD discussed the CND’s 
recommendations of 2007. The Committee did not carry out a 
review of dronabinol, but reinstated the recommendation made at 
the thirty-fourth meeting of the ECDD to move dronabinol and 
its stereochemical variants from Schedule II to Schedule III of the 
1971 Convention. The Committee decided that the previous ECDD 
40
W
H
O
 T
ec
hn
ic
al
 R
ep
or
t S
er
ie
s N
o.
 1
01
3,
 2
01
8
WHO Expert Committee on Drug Dependence   Fortieth report
decision on dronabinol and its stereochemical variants should stand, 
since it was unaware of any new evidence that was likely to materially 
alter the scheduling recommendation made at its thirty-fourth 
meeting. This recommendation was communicated by the Director-
General of WHO to the Secretary-General in October 2012. 
 ■ The CND reconsidered this issue in March 2013 at its fifty-sixth 
session. Concern was expressed by several delegations that, despite 
the recommendation received from WHO, no decision had yet 
been taken by the Commission to reschedule dronabinol and its 
stereochemical variants. A number of delegations noted that they 
were not able to support the recommendation made by WHO 
regarding dronabinol, as that recommendation could hinder efforts 
to prevent international cannabis abuse and could send a confusing 
message regarding the harm associated with the use of cannabis. It 
was suggested that WHO should continue to review dronabinol.
 ■ In March 2014, based on the recommendation made by the ECDD 
at its thirty-fifth meeting in 2012, the CND voted against moving 
dronabinol and its stereochemical variants from Schedule II to 
Schedule III of the 1971 Convention.
 ■ At its thirty-eighth meeting in 2016 the ECDD requested that 
Δ9-tetrahydrocannabinol (Δ9-THC) be pre-reviewed along with 
cannabis and cannabis resin, extracts and tinctures of cannabis, 
cannabidiol (CBD) and isomers of THC.
 ■ At its fortieth meeting in June 2018, the ECDD evaluated the 
above-mentioned pre-reviews and recommended to proceed to the 
critical reviews of cannabis and cannabis resin, extracts and tinctures 
of cannabis, Δ9-THC and isomers of THC at the forty-first meeting 
in November 2018.
9.20  Recommendation
Δ9-tetrahydrocannabinol (Δ9-THC ) refers to four stereoisomers of Δ9-THC. One 
of these stereoisomers is found in the cannabis plant and is also known by the 
INN dronabinol; it has recognized therapeutic uses. 
Chronic administration of Δ9-THC can induce physical dependence in 
laboratory animals and in humans. This has been demonstrated by the presence 
of withdrawal effects in animals and human subjects. The subjective effects of 
Δ9-THC when administered orally resemble those of cannabis. However, there is 
little evidence that oral Δ9-THC is used for non-medical purposes so as to cause 
a public health problem. 
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Δ9-THC (dronabinol) has approval in a number of countries for therapeutic 
indications including anorexia associated with weight loss in patients with AIDS 
and for nausea and vomiting associated with cancer chemotherapy. Δ9-THC 
(dronabinol) is routinely administered orally. 
Δ9-THC and its stereoisomers are listed in Schedule II of the Convention 
on Psychotropic Substances of 1971. In previous ECDD reviews, Δ9-THC, and 
especially dronabinol, had been considered in a synthetic form as a pharmaceutical 
preparation.
However, the Committee recognized that Δ9-THC, in particular, its 
active and naturally occurring stereoisomer, dronabinol, today also refers to the 
main psychoactive component of cannabis and cannabis-derived psychoactive 
products. In this form, dronabinol produces similar ill-effects, dependence and 
abuse potential to cannabis, which is placed under the 1961 Single Convention. 
A substance liable to similar abuse and productive of similar ill-effects to those 
of a substance already scheduled within the 1961 Convention would normally be 
scheduled in the same way as that substance. 
The Committee concluded that there is sufficient information to 
recommend a critical review of Δ9-THC at a future ECDD meeting in order to 
address the appropriateness of its placement within the Conventions. 
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10. Tetrahydrocannabinol (Isomers of THC)
10.1 Substance identification
The isomers of THC include six molecules that are identified in Schedule I of the 
Convention on Psychotropic Substances of 1971 including their stereochemical 
variants. These molecules with their chemical designations are listed in Table 
1. This entry in the schedules does not include delta-9-tetrahydrocannabinol 
(dronabinol).
Table 1.
Molecules of THC with their chemical designations
Molecule Substance identification
delta-6a(10a)-THC 7,8,9,10-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol
delta-6a(7)-THC (9R,10aR)-8,9,10,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-
dibenzo[b,d]pyran-1-ol 
delta-7-THC (6aR,9R,10aR)-6a,9,10,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-
dibenzo[b,d]pyran-1-ol 
delta-8-THC (6aR,10aR)-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-
dibenzo[b,d]pyran-1-ol 
delta-10-THC 6a,7,8,9-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol 
delta-9(11)-THC (6aR,10aR)-6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-9-methylene-3-
pentyl-6H-dibenzo[b,d]pyran-1-ol 
10.2 Chemistry
Methods have been developed for synthesis of these isomers.
10.3 Ease of convertibility into controlled substances
It is possible to convert (−)-trans-Δ8-THC into (−)-trans-Δ9-THC in laboratory 
facilities. 
10.4 General pharmacology
Δ8-THC and Δ9(11)-THC each produce Δ9-THC-like pharmacological effects in 
some animal models, whereas Δ10-THC does not. In humans, Δ8-THC is active 
when administered via several different routes, for example, oral, intravenous 
and inhalation. One stereoisomer of Δ6a,10a-THC ((S)-(−)- Δ6a,10a-THC) has 
psychoactive effects in humans similar to those of Δ9-THC but is quantitatively 
less potent (1:3 to 1:6), while the (R)-(+)-Δ6a,10a-THC, a second stereoisomer was 
inactive. Δ6a(10a)-THC also produces Δ9-THC-like effects when smoked, but the 
effects are less marked and have a shorter duration than those of Δ9 THC. None 
of the other isomers have been tested in humans. 
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10.5  Toxicology
Very little information exists on the toxicology of these isomers. There are limited 
preclinical toxicity data, and the isomers have not been administered to humans 
for extended periods. Limited toxicology data are available only for Δ8-THC, 
Δ6a,10a-THC and Δ9 (11)-THC.
The oral median lethal dose (LD50) of Δ8-THC in rats is 2000 mg/kg. 
Subcutaneous administration of Δ8-THC (up to 40 mg/kg) in rats prior to 
conception or during gestation did not have teratogenic effects. From the limited 
data available, Δ8-THC does not appear to be mutagenic. 
In mice, intravenous administration of 200 mg/kg Δ6a,10a-THC did not 
promote mortality. Δ6a,10a-THC does not reduce locomotor activity in mice. 
When administered to humans via smoking, Δ6a,10a-THC has much 
lower psychoactivity than Δ9-THC. The effects of smoking 15 mg Δ6a,10a-THC 
are less marked and have a shorter duration than a 12-mg dose of Δ9-THC. 
Δ6a,10a THC produced symptoms of light-headedness, numbness and tingling 
in the extremities and face, fatigue, cold perspiration, drowsiness and a feeling 
of relaxation. Impairment of thinking and the perception of time were less 
pronounced than with Δ9-THC.
Δ9 (11)-THC has an intravenous LD50 of 93 mg/kg in mice, which is double 
that found for Δ9-THC. 
10.6  Adverse reactions in humans
Only Δ8-THC and Δ6a,10a-THC have been tested in humans. The acute 
intoxicating effects of these molecules are similar in quality but less potent than 
acute doses of Δ9-THC. These molecules are not available for medical or non-
medical purposes, so little is known about their adverse effects in humans.
10.7  Dependence potential
No reports are available of studies that have assessed the potential of THC isomers 
for inducing physical dependence in laboratory animals or humans
10.8  Abuse potential
Data on the specific abuse potential of the six isomers are sparse. Of the six THC 
isomers reviewed here, preclinical assessment of abuse liability of three isomers 
has been evaluated for their pharmacological similarity to Δ9-THC, particularly 
in discrimination tests for substitution of the Δ9-THC discriminative stimulus. 
Δ9(11)-THC demonstrated the cannabimimetic tetrad of characteristic Δ9-THC-like 
effects, including suppression of locomotor activity, hypothermia, antinociception 
and ring immobility in animal studies, and was found to be several-fold less potent 
than Δ9-THC for each dependent measure. It has also been shown to produce 
Δ9-THC-like discriminative effects but at lower potency than Δ9-THC.
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Δ8-THC also produces Δ9-THC-like discriminative effects but at lower 
potency, and induces the characteristic tetrad of Δ9-THC-like effects as described 
in the paragraph above.
Δ10-THC, the third isomer that has been tested, did not produce Δ9-THC-
like discriminative effects. 
Few studies addressing the abuse potential of THC isomers have been 
undertaken in humans. The information on abuse potential of THC isomers 
is based primarily on early observational studies in which their subjective or 
physiological effects in human volunteers were compared to those reported 
following Δ9-THC administration. Of the six THC isomers reviewed here, only 
Δ8-THC and Δ6a,10a-THC have been tested in humans. The acute intoxicating 
effects of these substances are similar to those of Δ9-THC, but they are less potent. 
10.9  Therapeutic applications, extent of therapeutic use and 
epidemiology of medical use 
No medical or veterinarian use of these isomers has been reported.
10.10  Listing in the WHO Model List of Essential Medicines
None of the isomers is listed in the WHO EML (20th list) or the WHO Model List 
of Essential Medicines for Children (6th list).
10.11  Marketing authorizations (as a medicinal product)
There are no known marketing authorizations for these isomers.
10.12  Industrial use
These isomers have no known legitimate industrial use.
10.13  Non-medical use, abuse and dependence
No case reports of abuse or dependence relating to the use of these isomers were 
available. Between 1995 and 2014, one study reported a change in the potency of 
seized cannabis products in the USA. The data showed that before 2009, Δ8-THC 
had not been detected in cannabis seizures in the USA. A gradual increase in Δ8-
THC content was observed from 0.01% to 0.07% in 2014. However, compared to 
Δ9-THC, Δ8-THC content was lower by a factor of 10, and increasing potency of 
Δ8-THC did not appear to impact Δ9-THC concentrations. 
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10.14  Nature and magnitude of public health problems related to 
misuse, abuse and dependence
These isomers appear not to have been available for use. At present no public health 
problems (for example, driving under the influence of drugs or comorbidities) 
have been associated with their use.
10.15  Licit production, consumption and international trade
There is no known licit production of these isomers.
10.16  Illicit manufacture and traffic and related information
There appears to be no illicit manufacture or traffic of these isomers.
10.17  Current international controls and their impact
These isomers are included in Schedule I of the Convention on Psychotropic 
Substances of 1971.
10.18  Current and past national controls
The extent to which the isomers of THC, other than Δ9-THC, are controlled 
depends on the exact wording of the legislation in each jurisdiction. 
10.19  WHO review history
The isomers of Δ9-THC have never been subject to a critical review or pre-review 
by the ECDD. 
10.20  Recommendation
There are currently six isomers of THC listed in Schedule I of the 1971 Convention. 
Of the six THC isomers reviewed here, the abuse potential of only two, Δ8-THC 
and Δ6a,10a-THC, have been evaluated in a few human studies. These studies found 
that the acute intoxicating effects of these substances are similar to those of Δ9-
THC, but they are less potent. 
There are no reports that THC isomers induce physical dependence. There 
are no reported medical or veterinary uses of these isomers.
There is no evidence that any of these listed isomers are being abused or are 
likely to be abused so as to constitute a public health or social problem. However, 
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the Committee noted the potential difficulty of differentiating these six isomers 
(listed in Schedule 1 of the 1971 Convention) from Δ9-THC (listed in Schedule II 
of the 1971 Convention) using standard methods of chemical analysis owing to 
their chemical similarities. The Committee further noted that this is an important 
factor to consider in the scheduling of these isomers. 
The Committee concluded that there is sufficient information to 
recommend a critical review of the isomers of THC at a future ECDD meeting 
and to explore further the relevance of their current scheduling within the 1971 
Convention. 
11. Summary 
The fortieth ECDD undertook a critical review of cannabidiol (CBD) and 
pre-reviews of cannabis plant and resin; extracts and tinctures of cannabis; 
Δ9-tetrahydrocannabinol (Δ9-THC); and isomers of THC. The following 
recommendations were made: 
Cannabidiol 
The Committee recommended that preparations considered to be pure 
CBD should not be scheduled within the International Drug Control Conventions. 
Cannabis plant and resin
The Committee concluded that there is sufficient evidence to proceed to a 
critical review. 
Extracts and tinctures of cannabis
The Committee concluded that there is sufficient evidence to proceed to a 
critical review. 
Δ9-THC
The Committee concluded that there is sufficient evidence to proceed to a 
critical review. 
Tetrahydrocanabinol (Isomers of THC)
The Committee concluded that there is sufficient evidence to proceed to a 
critical review. 
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This report presents the recommendations of the 
fortieth WHO Expert Committee on Drug Dependence 
(ECDD). The ECDD is responsible for the assessment of 
psychoactive substances for possible scheduling under 
the International Drug Control Conventions. The ECDD 
reviews the therapeutic usefulness, the liability for abuse 
and dependence, and the public health and social harm 
of each substance. The ECDD will advise the Director-
General of WHO, to schedule or to amend the scheduling 
status of a substance. The Director-General will, as 
appropriate, communicate the recommendations to the 
Secretary-General of the United Nations, who will in turn 
communicate the advice to the Commission on Narcotic 
Drugs (CND). 
The report summarizes the findings of the fortieth 
meeting, which was dedicated to the review of cannabis 
and its component substances. This included a critical 
review of cannabidiol and pre-reviews of cannabis 
plant and resin; extracts and tinctures of cannabis; Δ9-
tetrahydrocannabinol ((Δ9-THC) ); and isomers of THC. 
The Committee recommended that preparations considered 
to be pure cannabidiol should not be scheduled within the 
International Drug Control Conventions. The Committee 
concluded that there is sufficient evidence to proceed to 
a critical review of cannabis plant and resin; extracts and 
tinctures of cannabis; Δ9-THC and isomers of Δ9-THC.
